NDLI: Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.

Please wait, while we are loading the content...

Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial.

Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.

The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.

Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in stroke patients: multicenter, randomized, open-label, phase 4, non-inferiority clinical trial.

Clustering medication adherence behavior based on beliefs in medicines and illness perceptions in patients taking asthma maintenance medications.

A comprehensive review of denosumab for bone metastasis in patients with solid tumors.

Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.

Incidence of postoperative residual neuromuscular blockade after general anesthesia: a prospective, multicenter, anesthetist-blind, observational study.

Burden of symptomatic uterine fibroids in Canadian women: a cohort study.

Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.

Impact of residential medication management reviews on anticholinergic burden in aged care residents.

Patiromer: a clinical review.

Why is residual neuromuscular blockade a universal issue?

Reaching more children with vaccines in developing countries: key challenges of innovation and delivery.

The profile of patients with chronic kidney disease who regularly present at an Australian general practice.

Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.

Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.

Year: 2016 Volume: 32 Issue: Supplementary 1

Year: 2016

Year: 2015 Volume: 31

Year: 2014 Volume: 30

Year: 2013 Volume: 29

Year: 2012 Volume: 28

Year: 2011 Volume: 27

Year: 2010 Volume: 26

Year: 2009 Volume: 25

Year: 2008 Volume: 24

Year: 2007 Volume: 23

Year: 2006 Volume: 22

Year: 1983 Volume: 8

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Song, Xue Cong, Ze Wilson, Kathleen
Description	Country affiliation: United States Author Affiliation: Song X ( a a Truven Health Analytics , Ann Arbor , MI , USA.); Cong Z ( b b Onyx Pharmaceuticals Inc. , South San Francisco , CA , USA.); Wilson K ( a a Truven Health Analytics , Ann Arbor , MI , USA.)
Abstract	OBJECTIVES: To describe multiple myeloma (MM) treatment patterns and comorbidities over time in the US. RESEARCH DESIGN AND METHODS: Study patients were newly diagnosed with MM (ICD-9-CM 203.0x) between 1 July 2006 and 31 March 2014 and had ≥6 months of data prior to the initial MM diagnosis in MarketScan Research Databases. Patients were followed until inpatient death or the end of data. First-line, second-line, and third-line treatment regimens were identified following diagnosis and were described over time based upon the start date of the first line of therapy (2006-2007, 2008-2014, 2013-2014). Comorbid conditions and disease-related complications were examined during the 6 months prior to the line of therapy start dates. RESULTS: A total of 24,507 MM patients were examined (mean age: 65.2 years, 54.1% male, mean follow-up: 23 months, 16.2% transplant). Across all lines of therapy, the proportion of patients on thalidomide-based regimens decreased over time. In the first line, bortezomib-based regimens became more common from 2006-2007 to 2008-2014 (2006-2007: 17.0%, 2008-2014: 44.3%, 2013-2014: 49.4%). In the second line, lenalidomide- and bortezomib-based regimens were the most common (2013-2014: lenalidomide: 28.9%, bortezomib: 26.2%). The combination regimen of lenalidomide + bortezomib became more common in the first and second lines. In the third line, carfilzomib- and/or pomalidomide-based regimens were 37.0% in 2013-2014. Skeletal-related events, hypertension, anemia, and chronic kidney disease were the most prevalent comorbidities and disease-related complications. During the 6 months prior to each line of therapy, the prevalence of the majority of the comorbidities and complications increased as patients progressed to higher lines of therapy. CONCLUSIONS: MM treatment patterns have been dynamic over time. Comorbid conditions and myeloma-related complications increase as patients progress and may worsen MM patients' prognoses over time. Combination regimens such as lenalidomide + bortezomib are more widely used as first- and second-line therapy. Newly approved agents (carfilzomib, pomalidomide) are the prevailing treatments in the third line and are under further investigation for earlier lines of therapy.
File Format	HTM / HTML
ISSN	03007995
Issue Number	1
Volume Number	32
e-ISSN	14734877
Journal	Current Medical Research and Opinion
Language	English
Publisher	Taylor & Francis
Publisher Date	2016-01-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Medicine Multiple Myeloma Drug Therapy Adult Aged Antineoplastic Combined Chemotherapy Protocols Therapeutic Use Bortezomib Administration & Dosage Comorbidity Female Humans Male Middle Aged Complications Retrospective Studies Thalidomide Analogs & Derivatives Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.

Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Role of consolidation/maintenance therapy in multiple myeloma.

Management of myeloma-associated renal dysfunction in the era of novel therapies.

High frequencies of response after limited primary therapy for multiple myeloma.

Recent advances in myeloma treatment.

Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.

Ten years of improvement in the management of multiple myeloma: 2000-2010.

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.

Similar Documents

Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.

Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Role of consolidation/maintenance therapy in multiple myeloma.

Management of myeloma-associated renal dysfunction in the era of novel therapies.

High frequencies of response after limited primary therapy for multiple myeloma.

Recent advances in myeloma treatment.

Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.

Ten years of improvement in the management of multiple myeloma: 2000-2010.

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.